1. Medtech Insight
  2. >>Device Area

Exec Chat: Glooko CEO Talks Differentiation, Collaboration And The Future Of Digital Diabetes Solutions

 
• By Barnaby Pickering

Medtech Insight talked to Russ Johannesson about Glooko’s connected diabetes care strategy, including its recent agreement with John Hopkins HealthCare Solutions and acquisition of Diabnext, a French competitor.

• Source: Alamy

Digital health company Glooko recently launched a new partnership with the Blossom Health platform, a diabetes self-management program designed by Johns Hopkins HealthCare Solutions, an analytics and consultancy organization attached to Johns Hopkins University in Maryland.

Blossom lets users track glucose levels – both past and present – dietary information and exercise levels. It also includes information about a patient’s general health background. Users are also...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.